Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab

IHG was more frequently associated with MASLD-HCC compared to controls, confirming preclinical data and suggesting biological differences between tumors, with potential implications for future research. MASLD should not be seen as a contraindication to immunotherapy.

Authors

Institutions

Publication Details

Journal
Liver Cancer
Published
2025-05-26
DOI
https://doi.org/10.1159/000545494
Citations
2
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
2.09

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab

Luca Ielasi, Leonardo Stella, Tiziana Pressiani, Stefania De Lorenzo et al.
2 citations
Liver Cancer
Colorectal Cancer Treatments and Studies
2.09
article

Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab

Luca Ielasi, Leonardo Stella, Tiziana Pressiani, Stefania De Lorenzo, Francesco Tovoli, Gianluca Svegliati‐Baroni, Ciro Celsa, Giuseppe Cabibbo, Alessandro Granito, Piera Federico, Benedetta Stefanini, Fabio Piscaglia, Caterina Vivaldi, Andrea Palloni, Claudia Campani, Sara Lonardi, Mariangela Bruccoleri, Maria Boe, Gianluca Masi, Bruno Daniele, Rusi Chen, Francesca Romana Ponziani, Lorenza Rimassa, Caterina Soldà, Giovanni Brandi, Ingrid Garajová, Bernardo Stefanini, Fabio Marra, Massimo Alberto Iavarone, Lorenzo Lani, Andrea Dalbeni, Alessandra Auriemma
article en
2 citations

Abstract

IHG was more frequently associated with MASLD-HCC compared to controls, confirming preclinical data and suggesting biological differences between tumors, with potential implications for future research. MASLD should not be seen as a contraindication to immunotherapy.

Liver CancerVol. 15(1)
Università Cattolica del Sacro Cuore (IT), University of Verona (IT), Marche Polytechnic University (IT), University of Parma (IT), Humanitas University (IT), University of Milan (IT), Agostino Gemelli University Polyclinic (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Ospedale Maggiore (IT), Istituto Oncologico Veneto (IT), Centro Clinico Nemo (IT), Azienda USL di Bologna (IT), Ospedale per gli Infermi (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), IRCCS Humanitas Research Hospital (IT), Azienda Ospedaliera Universitaria Pisana (IT), University of Florence (IT), University of Palermo (IT), University of Bologna (IT)
Università degli Studi di Palermo, Università di Bologna, Università degli Studi di Verona
Openalex Percentile: Top 12%
Colorectal Cancer Treatments and Studies
2.09
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.